Hugo Boss Sees Significant Increase In FY21 Group Sales, EBIT; Stock Down

German luxury fashion brand Hugo Boss AG (HUGSF.PK) Tuesday said it expects a significant increase in Group sales and EBIT for full year 2021.

The company projects strategic growth drivers China and Online to continue recording significant double-digit growth in the year.

Hugo Boss said it is currently not able to provide a precise outlook for fiscal year 2021 as a result of the ongoing short-term uncertainty related to extended lockdowns in key European markets.

The company further said it remains confident that the global retail environment will continue to gradually improve and that global business will recover noticeably in the further course of 2021.

In this context, the anticipated further progress in global vaccination campaigns and the gradual lifting of lockdowns and restrictions on public life are expected to fuel consumer sentiment, especially in the second half of the year, it said.

The company maintained its stated target of increasing own online sales to more than 400 million euros by 2022. the company is confident to cross the 300 million euros mark already in the course of this year.

Hugo Boss added that it will generate a significantly positive free cash flow in the future.

In Germany, Hugo Boss shares were losing around 1.7 percent to trade at 41.85 euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT